Xilio Therapeutics Presents Positive Preclinical Data for XTX601

Xilio Therapeutics announced new positive preclinical data for XTX601, a masked T cell engager targeting CLDN18.2, at the AACR Annual Meeting. The data highlighted XTX601's protease-dependent, tumor-selective activation and potent anti-tumor activity across multiple preclinical models. The drug was well tolerated in non-human primates, showing a favorable therapeutic index and supporting its potential to overcome systemic toxicities. Xilio plans to advance XTX601 into IND-enabling studies and submit an IND application in 2027.